Clinical Trial Update: ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer [EARLY_Phase 1]

View source ↗

Summary

This update describes the ASCEND-CRC early-phase 1 trial at MD Anderson aimed at profiling and targeting dynamic tumor resistance in metastatic colorectal cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Dynamic Tumor Resistance, Metastatic Colorectal Cancer | EARLY_Phase 1 | Status: NOT_YET_RECRUITING